TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
World game at war: why some European nations have threatened a World Cup boycott 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
MINNEAPOLIS, May 07, 2018 -- Inspire Medical Systems, Inc. (NYSE:INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today the closing of its initial public offering of 7,762,500 shares of its common stock at a public offering price of $16.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,012,500 additional shares. The gross proceeds from the offering are $124.2 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock were offered by Inspire. The shares began trading on the New York Stock Exchange on May 3, 2018 under the ticker symbol “INSP.”
BofA Merrill Lynch and Goldman Sachs & Co. LLC acted as joint book-running managers for the offering. Guggenheim Securities, Stifel and Wells Fargo Securities acted as co-managers for the offering.
A registration statement relating to these securities has been filed and was declared effective by the Securities and Exchange Commission. The offering of these securities was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting: BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or via email: [email protected]; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire Medical Systems’ proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Inspire Investor and Media Contact
Bob Yedid
LifeSci Advisors
[email protected]
646-597-6989
